Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | APAF1 | O14727 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | UBE2N | P61088 | 1/20 | 0.63 |
| ▸ | CFD | P00746 | 13/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10992549 | 0.89 | KDM4E (0.67) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL16689341 | 0.88 | CFD (0.64) | CFDHTR1AADRA2CADRA1AKCNH2 | |
| Water SCHEMBL10955232 | 0.88 | KDM4E (0.66) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL11256287 | 0.88 | KDM4E (0.66) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Water SCHEMBL10955227 | 0.88 | KDM4E (0.66) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL16689321 | 0.86 | KDM4E (0.63) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL16689308 | 0.86 | KDM4E (0.63) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL16689298 | 0.83 | CFD (0.61) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL17697908 | 0.79 | CFD (0.64) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL16689340 | 0.78 | HTR1A (0.67) | CFDHTR1AADRA2CADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| EP-2864322-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| EP-2864322-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-04-29 | — | — | EP | disclosed |
| WO-2013192345-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2013-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | CFB, CFH, TFPI | KDM4E 3839/4885APAF1 154/4885ALDH1A1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.